Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma
Liver Cancer · 21.10.2024 · 14 (3) · 334-350
DOI: 10.1159/000540857 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 21.10.2024. Verfasst von Xinyu Bi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical …. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality; it ranks as the second most common cause of cancer deaths in China. Most HCC patients are first diagnosed at an advanced stage. In recent years, targeted therapy combined with immunotherapy has become the preferred regimen for systemic treatment of intermediate-advanced HCC, while targeted therapy combined with immunotherapy plus local treatment could further improve the efficacy in many clinical studies. To better guide the clinical treatment for effective and safe combination therapy, our interdisciplinary panel on the treatment of intermediate-advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, interventional radiologists, and traditional Chinese medicine physicians have formulated this consensus based on current clinical studies and clinical medication experience for reference. The consensus contained 15 recommendations, including the applicable population and management, local treatment selection, conversion strategy, treatment strategy after tumor progression and management of common adverse reactions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Comprehensive Liver Cancer Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Interventional Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Hepatobiliary Surgery, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
- Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Zitieren
APA
Bi, X., Lu, Y., Chen, B., Yang, Z., Hong, Z., Wang, H., Sun, Y., Wang, X., Yuan, C., Zeng, D., Huang, Z., Zhou, A., Zhang, W., Du, S., Zhao, J., Zhou, J., Zhai, Y., Che, X., Zhao, H., …, & Cai, J. (2024). Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma. Liver Cancer, 14(3), 334-350. https://doi.org/10.1159/000540857
Vancouver
Bi X, Lu Y, Chen B, Yang Z, Hong Z, Wang H, et al. Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma. Liver Cancer. 2024;14(3):334-350. doi:10.1159/000540857
BibTeX
@article{Bi2024,
author = {Bi, Xinyu and Lu, Yinying and Chen, Bo and Yang, Zhengqiang and Hong, Zhixian and Wang, Hanping and Sun, Yongkun and Wang, Xiaodong and Yuan, Chunwang and Zeng, Daobing and Huang, Zhen and Zhou, Aiping and Zhang, Wen and Du, Shunda and Zhao, Jianjun and Zhou, Jianguo and Zhai, Yirui and Che, Xu and Zhao, Hong and Zhao, Haitao and Cai, Jianqiang},
title = {Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma},
journal = {Liver Cancer},
year = {2024},
volume = {14},
number = {3},
pages = {334--350},
doi = {10.1159/000540857}
}
EUVIMED